Author Archives: admin


Stem Cell Clinic > Articles by: admin

Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

By Global News Feed

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today reported that it received a notice (the “5250 Notice”) on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (“Rule 5250”) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Q3 Form 10-Q”) in a timely manner.

Original post:
Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

MEDSIR, Featured Company at the Shanghai International Medical Oncology Symposium (7th SIMOS)

By Global News Feed

BARCELONA, Spain, Nov. 29, 2024 (GLOBE NEWSWIRE) -- MEDSIR, a leading company dedicated to advancing independent clinical research in oncology on an international level, participated in the 7th Shanghai International Medical Oncology Symposium (SIMOS) in China, one of the most prestigious academic events in the global oncology field. Through this, the company reaffirms its commitment to scientific advancement, improving breast cancer treatments worldwide, and fostering the exchange of knowledge across regions.

Read more here:
MEDSIR, Featured Company at the Shanghai International Medical Oncology Symposium (7th SIMOS)

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

By Global News Feed

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:?HCM; HKEX:?13) today announces that following the contract renewal with the China National Healthcare Security Administration (“NHSA”), the updated National Reimbursement Drug List (“NRDL”) effective on January 1, 2025 will continue to include ORPATHYS® (savolitinib) at the same terms as the current two-year agreement.

See the rest here:
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

By Global News Feed

ZUG, Switzerland, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.

Originally posted here:
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million

By Global News Feed

VANCOUVER, British Columbia, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce that, in response to investor demand, the Company intends to increase the size of the previously announced $1.25 million non-brokered private placement (the “Offering”) to $2.5 million.

See the original post here:
Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million

→←